A symbolic milestone reached in our laboratory !
Last friday, we hit an impressive achievement: 300 experiments performed in only 20 months in our labs at the Légiapark. 🧪 That’s nearly one experiment per working day with an operational team of only two technicians supported by their lab manager. Thanks to the commitment, rigor, and resilience of the whole R&D team, we have developed a rare […]
Upcoming conferences
Our CEO, Pierre Vandepapelière, will be presenting at the 1st Annual European Neuroscience Innovation Forum on March 3rd, 2026 in Zurich: 03:40 pm – Track C – Room Berne Amyl has been selected for 2 on site presentations at ADPD 2026 conference that will take place on March 17-21, 2026 in Copenhagen. “Next-generation neurodegenerative diseases […]
2025 – A pivotal year for Amyl
This year, thanks to the hard work of our dedicated and passionate team, we successfully optimized our therapeutic candidate, achieving with a single product efficacy equal to or greater than three monoclonal antibodies — without their drawbacks — and significantly improving brain penetration. 🧠 This breakthrough paves the way for a revolutionary treatment for Alzheimer’s […]
PEGS Europe – Lisbon 2025
Our CSO and R&D Director have been proud to represent us at PEGS Europe in Lisbon, one of the leading international events in biotechnology, running from November 11 to 13. They have strengthened relationships with our trusted partners and engaged in exciting discussions with potential new service providers who can help us accelerate product development.
New Horizons in Neurodegeneration – Leuven 2025
Last Thursday and Friday, our team had the pleasure of participating in New Horizons in Neurodegeneration in Leuven — a fantastic opportunity to connect with fellow researchers and share cutting-edge developments in the field. We were proud to present our poster “Crossing Molecular Boundaries: An immunotherapeutic simultaneously targeting Amyloid β, Tau, and α-synuclein amyloid aggregates“, […]
Amyl Therapeutics is part of the Mediaplanet’s Life Sciences campaign
🔬 We’re excited to be part of Mediaplanet Belgium’s Life Sciences campaign, which showcases groundbreaking innovation in biotech and healthcare. This initiative reflects the shared ambition to accelerate scientific progress and bring meaningful change to patients’ lives. Let’s keep pushing the boundaries of science—together. Read our CEO’s interview here.
La biotech liégeoise Amyl Therapeutics ouvre une nouvelle voie contre l’Alzheimer
Pierre Vandepapelière, CEO Amyl Therapeutics: “Nous utilisons des technologies qui sont déjà validées et nous avons des résultats très positifs“. ©Valentin Bianchi / Hans Lucas La biotech liégeoise Amyl Therapeutics a réorienté ses développements vers l’Alzheimer. Elle pense avoir mis au point le traitement qui pourrait changer la vie de ceux qui en souffrent. Mais […]
World Alzheimer’s Day
Every day, and especially on this Wolrd Alzheimer’s Day , we are driven by a common mission: turning research into hope. At Amyl Therapeutics, our mission is clear: advance science to better understand and treat neurodegenerative diseases. Every breakthrough brings us closer to changing lives. We remain committed to building a future where Alzheimer’s disease no […]
BIO International Convention – Boston 2025
What a nice experience for our CSO to represent Amyl in Boston at the world’s largest biotech gathering ! More than 20,000 professionals from accross the globe attended. Damien Toulorge shared our technology and recent advances. This was a great recognition for our scientific team and a unique opportunity to highlight our commitment to neurodegenerative diseases.
Team Building Event 2025
What a day! We kicked off the morning paddling through the water on a kayak expedition, testing our balance, coordination, and—let’s be honest—our ability to laugh through unexpected tumbles! 🌊😆 The afternoon brought a collaboration course, where teamwork, strategy, and communication were key. Lots of laughs, a few splashes, and plenty of lessons in trust […]